PAX2 is a member of the paired box family of genes with an important role in kidney, genital tract and eye development. Another gene essential for kidney and genital tract development is the Wilms tumour gene, WT1. PAX2 and WT1 encode transcription factors expressed during fetal kidney development in patterns that overlap both spatially and temporally. The overlap of PAX2 and WT1 expression in fetal kidney prompted us to determine whether PAX2 regulates the WT1 gene. To investigate this possibility, the WT1 promoter and a series of WT1 promoter deletion fragments were cloned into a luciferase reporter vector, and used in cotransfection experiments with PAX2 expression constructs. PAX2 transactivated the WT1 promoter up to 35-fold in CHO-K1 cells, and from four-to sevenfold in 293 cells. Two regions of the WT1 promoter were required in the same promoter construct for ecient transactivation by PAX2 in CHO-K1 cells, and puri®ed recombinant PAX2 protein was found to bind to two sites in the WT1 promoter, at 7205/7230 and +377/ +402. Removal of WT1 promoter sequences containing the 7205/7230, or +377/+402 binding sites abolished transactivation of the WT1 promoter by PAX2 in CHO-K1 cells, and had a dierential eect on transactivation of the WT1 promoter in 293 cells, depending on the PAX2 isoform used. A fragment containing the 7205/ 7230 site alone could be transactivated by PAX2. These ®ndings suggest that PAX2 is a tissue-speci®c modulator of WT1 expression, and is involved in cell growth control via WT1.
Introduction
The mammalian kidney provides a valuable model system in which to analyse the molecular basis of cell growth and dierentiation (Bard et al., 1994) . Histological changes that occur during kidney development have been well characterised (Saxen, 1987) , and many inherited kidney developmental anomalies have been identi®ed (Hildebrandt, 1995) . A nephroblastoma (Wilms tumour), has been described that represents a malignancy arising from a failure of kidney dierentiation. Wilms tumour is a pediatric kidney cancer aecting approximately 1/10 000 children (Matsunaga, 1981) . Histologically, Wilms tumour contains tissue elements that resemble several stages of kidney development. A number of developmental genes, in particular WT1, N-myc, PAX2, and PAX8, are normally expressed in fetal kidney, and have been found in condensed blastema and epithelial elements within Wilms tumour (Pritchard-Jones et al., 1990; Nisen et al., 1986; Shaw et al., 1988; Dressler and Douglass, 1992; Eccles et al., 1995; Poleev et al., 1995) . Point mutations and deletions of WT1 (Gessler et al., 1994; Varanasi et al., 1994) , occur in approximately 10% of Wilms tumours.
The Wilms tumour suppressor gene, WT1, encodes a transcription factor with four carboxy-terminal zinc ®nger domains (Call et al., 1990; Hastie, 1994) , which is expressed in fetal kidney condensed mesenchyme, renal vesicle and glomerular epithelium (PritchardJones et al., 1990) . Alternative splicing of exon 5, or of nine base pairs within exon 9 which encode lysine, threonine and serine (KTS), generates four WT1 protein isoforms exhibiting dierent DNA-binding speci®cities Bickmore et al., 1992) . The human WT1 promoter is G ± C rich, lacks a TATA box or CCAAT motif, and has multiple WT1 and SP1 binding sites (Hofmann et al., 1993; Campbell et al., 1994; Fraizer et al., 1994; Rupprecht et al., 1994; Gessler and Bruns, 1993) . WT1 has been shown to negatively autoregulate its own expression (Rupprecht et al., 1994; Malik et al., 1994) . Although WT1 expression patterns are tissue-speci®c, factors which govern tissue-speci®c expression of WT1 are not known, except GATA1 which binds a 3' enhancer binding element, regulating WT1 during haematopoiesis (Fraizer et al., 1994) . When transfected into heterologous cell lines the WT1 promoter is active in all cell lines tested (Hofmann et al., 1993; Campbell et al., 1994; Fraizer et al., 1994; Rupprecht et al., 1994) . WT1 is critically involved in kidney and genital tract development, as homozygous mutations of murine WT1 are embryonic lethal resulting in renal agenesis, genital tract abnormalities, cardiac malformations and mesothelial abnormalities (Kriedberg et al., 1993) . Microinjection of WT1 cDNA into quiescent or early to mid G 1 phase NIH3T3 cells inhibits serum-induced cell cycle progression into S-phase (Kudoh et al., 1995) . In addition, constitutive expression of WT1 in COS-1 cells inhibits large tumour antigen (TAg) and SV40 origin-dependent DNA replication (Anant et al., 1994) . These ®ndings suggest that WT1 has growth regulatory and tumour suppressor functions.
PAX2 encodes a protein with an amino-terminal paired box DNA-binding domain, a conserved octapeptide domain, and a proline-rich carboxyterminal domain (Dressler et al., 1990; Eccles et al., 1992) . The presence of the paired-type DNA-binding motif identi®es PAX2 as a member of the paired box (PAX) family of genes, which have been shown to have important roles in vertebrate development (Strachan and Read, 1994) . To date, nine mammalian PAX genes have been identi®ed (Stapleton et al., 1993) most of which encode transcriptional regulators (Treisman et al., 1991) . PAX proteins have so far been shown to regulate CD19 (Kozmik et al., 1992) , thyroglobulin, thyroperoxidase (Zannini et al., 1992) , NCAM (Holst et al., 1994) , aA-crystallin (Cvekl et al., 1995a) , deltaIcrystallin (Cvekl et al., 1995b) , zeta-crystallin (Richardson et al., 1995) and c-met (Epstein et al., 1996) , and PAX proteins may regulate genes both by transcriptional activation and inhibition (Chalepakis et al., 1994; Dor¯er and Busslinger, 1996) . PAX2 has been shown to bind to sequences containing a core DNA sequence motif, GTTCC (Fickenscher et al., 1993) , and more recently to a 17 bp consensus binding site (Epstein et al., 1994; Czerny and Busslinger, 1995) .
PAX2 is expressed in fetal kidney simultaneously with WT1 (Pritchard- Dressler and Douglass, 1992; Eccles et al., 1992) . The expression patterns of PAX2 and WT1 are tightly co-ordinated as the renal mesenchyme dierentiates into renal vesicles. PAX2 is expressed in the ureteric bud, the condensed mesenchyme and renal vesicles in human fetal kidney, but expression declines in epithelial structures before the formation of the glomerulus (Eccles et al., 1992) . We have previously noted that between early and late stages of human kidney dierentiation, WT1 is expressed at two dierent levels (Eccles et al., 1995) . While PAX2 is expressed, WT1 is expressed at relatively low levels in proliferating mesenchyme, renal vesicles and proximal S-shaped bodies. At a later stage when PAX2 expression has attenuated, WT1 expression levels increase to higher levels in the cells of the distal S-shaped body, including the newly formed glomerular podocytes. WT1 has been shown to transcriptionally repress PAX2 promoter activity, and may be responsible for the attenuation of PAX2 expression during kidney morphogenesis (Ryan et al., 1995) .
The PAX2 gene contains at least 12 exons (Sanyanusin et al., 1996) , several of which are alternatively spliced. PAX2 cDNAs lacking exon 10, but either containing exon 6 (PAX2a), or lacking exon 6 (PAX2b) have been described in mice (Dressler and Douglass, 1992) , and PAX2 cDNAs lacking exon 6, but either containing exon 10 (PAX2c) or lacking exon 10 (PAX2b) have been described in humans (Ward et al., 1994) . The predicted PAX2 isoform encoded by PAX2c contains a polypeptide sequence encoded by exon 10, and a proline-, serine-and threonine-rich COOH-terminal portion containing a dierent amino acid sequence than PAX2a or PAX2b (Ward et al., 1994) . The alternative COOH-terminal sequence in the PAX2c isoform is caused by a frame-shift alteration which is introduced when the 83 bp sequence of exon 10 is spliced (Ward et al., 1994) . A premature translation stop signal at the end of exon 11 arising from the frame-shift in PAX2c precludes the translation of exon 12 sequences in the predicted PAX2c protein (Ward et al., 1994) .
Like WT1, PAX2 plays an important role in kidney development. Constitutive PAX2 gene expression in transgenic mice results in multicystic and dysplastic kidneys in 18 day gestation fetuses and newborn pups (Dressler et al., 1993) . Heterozygous PAX2 mutations in mice result in eye abnormalities, renal hypoplasia and end-stage renal failure. Homozygous PAX2 mutations are embryonic lethal resulting in eye and CNS anomalies and complete agenesis of the kidneys and genital tract (Keller et al., 1994; Torres et al., 1995 Torres et al., , 1996 . In humans, hemizygous germline mutations of PAX2 have been associated with optic nerve colobomas, vesicoureteric re¯ux, renal hypoplasia and chronic renal failure (Sanyanusin et al., 1995a) . Mutations of PAX2 have also been found in patients with renalcoloboma syndrome (Sanyanusin et al., 1995b) .
Recent studies suggest that PAX2 represses the activity of the p53 promoter (Stuart et al., 1995) and activates expression of En-2 (Song et al., 1996) . Coexpression of PAX2, WT1, p53 and N-myc mRNA in human fetal kidney prompted us to analyse the regulation of these gene promoters by PAX2. Here we show that up to 35-fold transactivation of the WT1 promoter occurred in CHO-K1 cells co-transfected with reporter constructs containing the WT1 promoter and PAX2 expression constructs, and from four-to sevenfold transactivation of the WT1 promoter occurred in 293 cells. We found that PAX2 binds to the WT1 5' regulatory sequences at sites distal (7205 to 7230) and proximal (+377 to +402) to the major human transcription start site (Fraizer et al., 1994) . Two regions of the WT1 promoter were required for ecient transactivation by PAX2, and removal of WT1 promoter sequences containing either the 7205/7230, or the +377/+402 binding sites abolished transactivation of the WT1 promoter by both PAX2b and PAX2c in CHO-K1 cells, but had a dierential eect on transactivation of the WT1 promoter by PAX2 in 293 cells. We also found that a fragment containing the 7205/7230 site alone could be transactivated by PAX2. These data suggest that PAX2 transcriptionally regulates the Wilms tumour suppressor gene, WT1, during renal organogenesis. By regulating WT1, PAX2 may indirectly control renal cell growth.
Results
Analysis of p53, N-myc and WT1 gene promoters for regulation by PAX2
To determine whether PAX2 could regulate the p53, Nmyc or WT1 gene promoters we co-transfected CHO-K1 cells with PAX2 expression vectors and luciferase reporter constructs under the control of each gene promoter (see Figure 1a) . The human WT1 promoter was a SacI-PstI fragment (7873 to +425 relative to the major human transcription start site, Figure 1a ), which has previously been shown to contain all the cis elements required for transcriptional activity in 293 cells (Campbell et al., 1994; Fraizer et al., 1994) . PAX2 has previously been shown to repress activity of the p53 promoter (Stuart et al., 1995) , but it is possible that by using a larger fragment of the p53 promoter a dierent response to PAX2 might be observed, especially if additional regulatory sequences were included. We therefore chose for the human p53 promoter, a 532 bp fragment which has been shown to be transcriptionally active (Tuck and Crawford, 1989) , and is larger than the construct previously been shown to be regulated by PAX proteins in NIH3T3 cells (Stuart et al., 1995) . The human N-myc gene promoter was a 2029 bp fragment, including the transcription start and 1.86 kb of 5'¯anking sequence (Takehana et al., 1991) . For PAX2 expression, two alternatively spliced forms of PAX2 cDNA, PAX2b and PAX2c (Ward et al., 1994) were cloned into the human cytomegalovirus promoter construct RcCMV, and used in co-transfection assays (Figure 1b) .
Co-transfection of CHO-K1 cells with PAX2 and the p53 promoter resulted in signi®cant repression of p53 promoter activity by the PAX2b isoform (Figure 2 ). However, co-transfection of the p53 promoter with an empty CMV expression vector also repressed the activity of the p53 promoter by the same amount as with the PAX2b expression vector (Figure 2) . This eect, which may be due to transcriptional squelching by the CMV promoter in the expression construct, suggests that co-transfection of CMV expression vectors with promoter-reporter constructs can result in artifactual repression (Reddy et al., 1995) . In contrast to the repression of p53 observed with PAX2b, the expression of the p53 promoter was activated fourfold by PAX2c in CHO-K1 cells (Figure 2 ).
The N-myc promoter was activated approximately twofold by PAX2b and PAX2c in CHO-K1 cells, and the WT1 promoter was activated approximately nineto tenfold by either PAX2 isoform in CHO-K1 cells (Figure 2 ). Co-transfection of the cells with the WT1 promoter and an empty CMV expression vector resulted in no change of activity (Figure 2 ). These results suggest that the WT1 promoter may be transcriptionally activated by PAX2.
The human WT1 5' regulatory region contains four DNA sequences with homology to the PAX2 consensus binding site A 17 bp consensus DNA sequence for the binding of PAX2, PAX5 or PAX8 protein has previously been identi®ed (Czerny and Busslinger, 1995) . Analysis of the SacI-PstI WT1 promoter fragment for DNA sequences containing homology to the consensus PAX2 binding site revealed four regions with 410/17 bp matches which we have designated as Consensus-Like Binding Sites 1 ± 4 (CLBS1 to CLBS4) (Figure 3 ). The four homologous sequences were located close together, within a 267 bp region, between 753 and 7319 bp relative to the major human transcription start site (see Figure 4) . Shown are the promoterreporter constructs of the p53 promoter, pGLp53p, the N-myc promoter, pGLN-mycB, and the WT1 promoter, pGLWTpS-P, cloned into the plasmid pGL2 basic. The transcription start sites (arrow) of each promoter are shown, as well as the indicated restriction sites. Bm, BamHI, Bn, BanII, Bs, BssHII, E, EcoRI, Ea, EagI, H, HindIII, Ps, PstI, Pv, PvuII, S, SacI, X, XbaI. (b) Diagram of the PAX2 expression constructs, PAX2b and PAX2c, cloned into plasmid RcCMV. At the top is a depiction of the intron-exon structure of the PAX2 coding region. The DNA binding domain is shown (heavy underline), as well as two alternatively spliced exons, exon 6 (shaded box) and exon 10 (black box). PAX2b lacks exons 6 and 10, while PAX2c lacks exon 6, but contains exon 10 (black box). Exon 11 in PAX2c (hatched box) encodes a proline-, serine-, threonine-rich Cterminus with a dierent amino acid sequence than encoded by exons 11 and 12 in PAX2b. The numbers adjacent to each construct represent the start and ®nish of each DNA segment, according to the nucleotide sequence reported for each gene. Scale bar represents 200 bp The response of the pGLWTpS-P fragment of the WT1 promoter to PAX2 in CHO-K1 cells has already been determined above (Figure 2 ). To identify regions within the WT1 5' regulatory region responsible for PAX2-mediated activity, deletions of distal portions of the fragment relative to the transcription start site were made (pGLWTpX-P and pGLWTpH-P, Figure 4 ), and these deletion constructs were co-transfected into the human embryonic kidney-derived cell line 293, as well as CHO-K1 cells, along with PAX2 expression constructs. Co-transfection of an XbaI-PstI fragment of the WT1 promoter, pGLWTpX-P (7270 to +425), into 293 or CHO-K1 cells with either the PAX2b or PAX2c expression constructs resulted in a four-to 35-fold increase in luciferase reporter activity when compared to the basal activity of the reporter construct in cells transfected without PAX2 expression constructs ( Figure 4 ). In contrast, there was no activation of a HindIII to PstI fragment of the WT1 promoter, pGLWTpH-P (7215 to +425), in 293 or CHO-K1 cells in response to co-transfection with the PAX2b expression construct (Figure 4 ). Co-transfections done with pGLWTpH-P and a CMV-luciferase construct resulted in no change of pGLWTpH-P activity (data not shown). There was also no activation of the pGLWTpH-P fragment by PAX2c in CHO-K1 cells, but the activity of pGLWTpH-P was enhanced by PAX2c in 293 cells. This dierential eect is reminiscent of the dierential eect observed above when PAX2c and PAX2b constructs were co-transfected with the p53 promoter in CHO-K1 cells ( Figure  2 ). The key ®nding from these results is that a change in responsiveness of the WT1 promoter to PAX2 occurred in 293 and CHO-K1 cells following deletion of a 55 bp region between the XbaI and HindIII Figure 3 Alignment of four consensus-like binding sites (CLBS1 ± CLBS4), which were identi®ed in the WT1 promoter by sequence homology to the PAX2/5/8 consensus binding site sequence. The highlighted sequences in CLBS1 ± CLBS4 delineate the nucleotides which match the PAX2/5/8 consensus sequence (Czerny and Busslinger, 1995) . CD19 is the CD19 (A-ins) sequence which binds PAX5 (and PAX2) with high anity (Czerny et al., 1993) . The column at right shows the extent of homology in each consensus-like binding site. Four bases are conserved in the CD19 and CLBS3 sequences that may be important for DNA binding (arrows), because although the sequences of CLBS2 and CLBS4 are also very similar to the consensus, they do not bind PAX2, and dier from CLBS3 or the PAX2/5/8 consensus binding site at these three positions Figure 4 (a) Diagram showing the human WT1 promoter and WT1 promoter deletion constructs. The position of the major human transcription start site is shown (arrow, +1) (Fraizer et al., 1994) , as are four potential PAX2 binding sites with homology to the consensus PAX2/5/8 binding site (CLBS1 ± CLBS4) (black boxes, left to right, respectively), and the CR region, which corresponds to a homologous region called the`conserved region' (CR) (771 to 733 of murine WT1 promoter) in the murine WT1 promoter, which was transactivated by PAX2 and PAX8 (striped box) . Restriction sites are S, SacI; X, XbaI; H, HindIII; B, BssHII; E, EagI; P, PstI. The largest construct, pGLWTpS-P (7873/+425) is the same as shown in Figure 1a . Deletions were made from each end of the SacI-PstI fragment, using restriction enzyme sites, as indicated in the name of each deletion construct. The relative basal activities of three of the constructs in 293 cells, when PAX2 expression plasmids were absent, were in agreement with relative basal WT1 promoter activities that others have reported (Campbell et al., 1994; Fraizer et al., 1994) . The numbers to the left of the ®gure refer to each construct as used in part B. (b) Shown is the activation, or repression, of luciferase activity in 293 or CHO-K1 cells cotransfected with PAX2 expression and WT1 promoter deletion constructs, as compared with the basal activity of each promoter construct alone (open bars). The WT1 promoter deletion constructs are indicated by the numbers below the graphs and correspond to the numbers at the left of each construct in part A. When PAX2b (shaded bars) or PAX2c (striped bars) was transiently cotransfected with the WT1 promoter reporter constructs into CHO-K1 or 293 cells, luciferase activities were measured, and the results graphed as relative light units (RLU) of activity. All values represent at least four experiments done in triplicate. Error bars represent the standard error of the mean (s.e.m.) restriction sites (7270 to 7215). These data suggest that an important PAX2 responsive element may be located between 7215 and 7270 bp upstream of the major human transcription start site that is necessary for transcriptional activation of the WT1 promoter by PAX2.
Proximal and distal portions of the WT1 promoter are both required for ecient transcriptional activation by PAX2
Deletions were also made of proximal portions of the pGLWTpS-P fragment between positions 7270 and +425, to examine the relative contributions of both the XbaI and HindIII (7215 to 7270) region and proximal portions of the WT1 promoter to transcriptional activation in response to PAX2. Figure 4 shows three deletion constructs, pGLWTpS-B, pGLWTpS-H, and pGLWTpS-X that were assayed in co-transfections of 293 and CHO-K1 cells with PAX2b or PAX2c. We observed a signi®cant repression of basal activity of pGLWTpS-B, a SacI to BssHII fragment of the WT1 promoter (7873 to +116), when CHO-K1 cells were co-transfected with PAX2b or PAX2c expression constructs (Figure 4 ). In contrast, we observed a twoto threefold increase in luciferase activity when 293 cells were co-transfected with pGLWTpS-B and PAX2b or PAX2c. A smaller SacI to HindIII fragment of the WT1 promoter, pGLWTpS-H (7873 to 7215) had very little basal activity in CHO-K1 and 293 cells, because it did not contain a transcription start site. This fragment was minimally activated by PAX2 in 293 cells, and repressed by PAX2 in CHO-K1 cells (Figure 4) . A smaller fragment again, pGLWTpS-X (7873 to 7270) SacI to XbaI, had essentially no basal activity, and upon transfection with PAX2b or PAX2c in CHO-K1 or 293 cells resulted in only a small activation. These results suggest that constructs containing the XbaI to HindIII (7215 to 7270) region, but missing the proximal portions (+116 to +425) of the WT1 promoter, are not sucient to support transcriptional activation of the WT1 promoter by PAX2 in CHO-K1 cells. On the other hand, a construct containing only the proximal regions of the WT1 promoter, pGLWpE-P (+270 to +425) demonstrated low basal activity, and was minimally activatedÏ , CLBS3 and CLBS4) (dark shaded boxes), and the CR region which has homology to the putative PAX2 and PAX8 binding sites of the murine WT1 promoter (see Figure 4 legend) (striped box) . Also shown are the double-stranded oligonucleotides, I ± V, which were used in binding and competition experiments. PAX2 protein binds to two dierent sequences of WT1 5' regulatory region in DNaseI footprint assays
The XbaI ± HindIII (7270 to 7215) segment of the WT1 5' regulatory region contains two of the four consensus-like binding sites containing homology to the PAX2 consensus binding site (CLBS2 and CLBS3 in Figure 5a ) that were identi®ed in the SacI to PstI fragment. To determine whether a binding site for PAX2 protein is located in the XbaI ± HindIII region, two overlapping double-stranded oligonucleotides were designed, I and II (Figure 5a ). Oligonucleotide I contained CLBS3, while oligonucleotide II contained CLBS2. Oligonucleotide I demonstrated PAX2 binding activity in electromobility shift assays (EMSA) ( Figure  5b , lane 1), which could be competed with an excess of unlabelled oligonucleotide I, but not oligonucleotide II ( Figure 5b , lanes 2 and 3). The sequence of oligonucleotide I was divided into three overlapping double-stranded sequences (oligonucleotides III ± V, Figure 5a ), and one of these oligonucleotides (oligonucleotide V) contained PAX2 binding activity ( Figure 5c , lane 2). The consensus-like binding site, CLBS3, was observed to be near one end of oligonucleotide V (Figure 5a ). Primers were designed to generate a PCR product encompassing both oligonucleotides I and II (Figure 5a ). The subcloned PCR product was then used to generate a probe for DNaseI footprinting. Recombinant human PAX2 protein was found to bind to a 26 bp sequence containing CLBS3 between nucleotides 7205 and 7230 inclusive, relative to the WT1 transcription start ( Figure 6a , lane 2). The binding of PAX2 protein to this sequence in DNaseI footprinting could be competed with an excess of unlabelled oligonucleotide I (Figure 6a , lane 3), but not with oligonucleotide II (not shown), demonstrating that binding of PAX2 protein to this sequence was speci®c. Another potential PAX2 binding site in oligonucleotide I could be the region of the human WT1 promoter (see Figure 5a ) corresponding to a homologous region called the`conserved region' (CR) (771 to 733 of murine WT1 promoter) in the murine WT1 promoter that was transactivated by PAX2 and PAX8, and that has been shown to bind PAX8 . Upon designing a double-stranded oligonucleotide containing the CR sequence (oligonucleotide CR, see Figure 5a ) and analysing this sequence in EMSA with PAX2, no binding of PAX2 protein was observed (Figure 5c , lane 8). In addition we found that PAX2 protein did not bind to consensus-like binding site 4, CLBS4, which is proximal to the CR region (Figure 5c , lane 5).
To identify any other PAX2 binding sites that might be located between +116 to +425 relative to the WT1 transcription start, an EagI to PstI restriction fragment was isolated from the WT1 proximal¯anking sequences, and used as a probe for DNase I footprinting with recombinant bacterial PAX2 protein ( Figure  6b ). PAX2 protein was found to bind to a 26 bp sequence between +377 and +402 inclusive ( Figure  6b , lane 2), and binding of PAX2 protein to this sequence could be competed with an excess of unlabelled oligonucleotide I (Figure 6b, lane 3) .
Sequence comparison between murine and human PAX2 binding sites in the WT1 5' regulatory region
We compared the sequences in the human WT1 5' regulatory region, which bound to PAX2 in DNaseI footprint analysis, to the equivalent sequences in the murine WT1 promoter and also to the consensus PAX2/5/8 binding site. The PAX2 binding site between 7205 and 7230 in human WT1 showed only 15/26 bp homology to the corresponding murine sequence (Figure 6c) , although four nucleotides which may be important for PAX2 binding (see Figure 3 legend) were conserved (Figure 6c, asterisks) . In constrast the PAX2 binding site between +377 and +402 in human WT1 showed 22/26 bp homology with the murine WT1 promoter sequence, but very little similarity to the PAX2/5/8 consensus binding site. Figure 6e shows the binding sites of PAX2 that we have determined in relation to the sites of WT1 protein binding.
PAX2 transcriptionally activates a 127 bp fragment of the WT1 5' regulatory region containing a single PAX2 binding site when co-transfected into 293 or CHO-K1 cells
The 127 bp fragment that was used for DNaseI footprinting of the 7205 to 7230 PAX2a) was subcloned into the luciferase reporter plasmid, pGL-2 promoter, generating the plasmid pGLWTp#1 to be used in co-transfection assays with PAX2 expression constructs. Upon co-transfection of reporter and PAX2 expression constructs into 293 or CHO-K1 cells, it was found that luciferase activity was enhanced between two-and sixfold in both cell lines, relative to baseline activity of pGLWTp#1 (Figure 7 ).
Discussion
The identi®cation of positive regulation of WT1 by PAX2 in this study suggests that, by directly regulating the WT1 promoter, PAX2 may control the level of WT1 mRNA in cells. We found that both PAX2b and nucleotides are shown with a vertical line. Highlighted nucleotides delineate the sequences that match the consensus PAX2/5/8 binding site. Asterisks show nucleotides which may be important for DNA binding by PAX2, because three of these nucleotides were present in the consensus PAX2/5/8 binding site, but were dierent in CLBS2 and CLBS4, which did not bind PAX2 (see PAX2c isoforms could activate the full-length WT1 promoter via at least one, and possibly two cooperating PAX2 binding sites. The identi®cation of two PAX2 binding sites in the WT1 promoter is similar to the results obtained by Song et al. (1996) , who found that two PAX-binding-sites were necessary for full expression of the En-2 gene promoter in vivo.
During the preparation of this manuscript there were two reports of transactivation of the murine WT1 promoter by murine PAX2 and PAX8 at sites that were 19 and 42 nucleotides proximal to our sequence, respectively (733 to 771 in the murine sequence) . The reported sequences included GTTC and TGCCC core binding motifs for PAX2 and PAX8, respectively, which are highly conserved between humans and mice. However, while demonstrated binding and transactivation of the WT1 promoter in this region by PAX8, were unable to demonstrate binding of murine PAX2 to this region in gel shift assays. Their results, while leading to the same conclusion as ours, were disimilar in other respects. We have shown that human PAX2 protein does not bind the sequence in the WT1 promoter which ®nd is transactivated by PAX2. One of our constructs (pGLWTpH-P) which contained the region identi®ed by was non-responsive to PAX2 in CHO-K1 cells.
It therefore seems unlikely that the murine WT1 promoter is directly regulated by PAX2 via the region that have identi®ed. It is possible that the results obtained with PAX2, were due to co-interaction of PAX2 with another protein that bound to the 733 to 771 region. Moreover, core PAX binding motifs containing 5'-GTTCC-3' have not so far been identi®ed in any DNA sequences bound by PAX proteins (Zannini et al., 1992; Czerny et al., 1993; Epstein et al., 1994) .
We have also examined the interaction of PAX2 with an adjacent consensus-like binding site, CLBS4, and found that this site also does not bind PAX2, and is therefore also unlikely to be important in PAX2-mediated regulation of the WT1 promoter. To determine whether any other regions of the WT1 promoter contained PAX2 binding sites we analysed binding of PAX2 protein to seven overlapping PCR products spanning sequences of the human WT1 promoter between 7873 to +382, including CLBS1 (TAW, unpublished) . In these assays we found binding only to regions that included the proximal and distal binding sites that we have already identi®ed, suggesting that PAX2 does not interact with more than two regions of the WT1 promoter.
A region of high homology exists between human and mouse WT1 promoters from 7196 through to the coding region of the WT1 gene. There are several transcription start sites within this region (Homan et al., 1993; Campbell et al., 1994) . The PAX2 binding site at 7205/7230 that we have identi®ed is located approximately 100 bp upstream from the nearest transcription start site (Campbell et al., 1994) . The 7205/7230 PAX2 binding site was immediately adjacent to regions of high homology between mice and humans, and showed 15/26 bp homology with the corresponding sequence in mice. While the human PAX2 binding site contained a 13/17 bp match to the consensus PAX2 binding site, the corresponding murine sequence showed only a 7/17 bp match. On the other hand, the murine sequence contained three nucleotides which were identical to the human sequence (see asterisks Figure 6 ) in positions which appeared to be important for PAX2 binding, as determined by comparing the sequences of CLBS2, CLBS3 and CLBS4 with each other, to CD19, and to the consensus PAX2/5/8 binding site (see Figure 3 legend). For example, it can be seen that the arrowed nucleotides (Figure 3) are the key nucleotides in CLBS2 or CLBS4 that are dierent from either CLBS3, CD19 or the consensus PAX2/5/8 binding site. It is possible that this PAX2 binding site has evolved separately in humans and mice to meet the speci®c requirements of each species with respect to kidney size. In contrast, the PAX2 binding site at +377 to +402 was highly conserved between humans and mice, but did not resemble any other known PAX binding site. The functional role of the +377/+402 site appears to be to cooperate with the 7205/7230 binding site in order to allow the ecient transactivation of the WT1 promoter by PAX2. However, further characterisation of the proximal PAX2 binding site will be required to determine whether it de®nes a new type of PAX2 responsive sequence. It is of interest that this site is located at +377 to +402 relative to the transcription start, as PAX proteins have been shown Figure 7 Transcriptional activation of a 127 bp fragment of the WT1 promoter by PAX2. A 127 bp PCR product encompassing sequences covered by oligonucleotides I and II (distal region; 7172/7299) was subcloned into the SmaI site of pGL2 promoter to make pGLWTp#1, and used in co-transfection assays in 293 and CHO-K1 cells. The fold activation of pGL/WTp#1 was measured with and without added PAX2 expression plasmids (PAX2b and PAX2c) to regulate the activity of target genes irrespective of the position of the PAX binding element relative to the transcription start site in reporter constructs (Dor¯er and Busslinger, 1996) . found that endogenous WT1 expression of K562 cells was enhanced by ectopic expression of murine PAX2, implying that the endogenous WT1 gene may indeed be transcriptionally regulated by PAX2. In contrast, Torban and Goodyer (1996) showed that modulation of PAX2b expression in 293 cells with a tetracycline-responsive promoter did not aect proliferation of the cells, or the level of WT1 mRNA. Our results are consistent with conclusions from both of these studies, in that PAX2b expression had little eect on activity of the full-length WT1 promoter in 293 cells, but PAX2b had a strong activating eect on the full-length WT1 promoter in CHO-K1 cells. Although 293 cells were derived from human embryonic kidney by immortalisation with fragments of adenovirus DNA (Graham et al., 1977) , the endogenous expression of WT1 is low in 293 cells when compared with human fetal kidney , whereas CHO-K1 cells express little or no WT1 (MRE, unpublished). Indeed, the exact molecular mechanism by which 293 cells were immortalised is not known, and it is possible that transcriptional control of the endogenous WT1 gene in 293 cells is in¯uenced by factors involved in the immortalisation process. This may be the reason why fragments of the WT1 promoter were not activated by PAX2 as strongly in 293 cells as in CHO-K1 cells. In general the response of the WT1 promoter in 293 cells was similar to, but smaller than, that in CHO-K1 cells, except that PAX2 was able to stimulate transcription of WT1 promoter fragments containing the 7205/7230 PAX2 binding site in the absence of the +377/+402 binding site in 293 cells. The reason for this may be that 293 cells contain additional cooperating transcription factors that were not present in CHO-K1 cells.
The dierential activation of the WT1 promoter by PAX2b and PAX2c was most pronounced with the pGLWTpH-P fragment in 293 cells. In most cases PAX2c was observed to transactivate the WT1 promoter more strongly than PAX2b, while PAX2b repressed more strongly than PAX2c. The dierential activation induced by PAX2b and PAX2c may be due to the alternative COOH-termini of the two PAX2 isoforms, which arises from alternative splicing of exon 10 in PAX2 (Ward et al., 1994) . Alternative COOH-terminal regions of PAX2b and PAX2c may interact with dierent sets of cooperating transcription factors. The COOH-terminal region of PAX2c is proline-, serine-and threonine-rich and shares no similarity with PAX2b (Ward et al., 1994) , but does contain a region of signi®cant similarity to the PAX8c isoform (Poleev et al., 1995) . PAX8c also contains a frame shift in the carboxy-terminal region caused by alternative splicing. Alternative splicing of exon 10 in PAX2 may exchange an inhibitory carboxy-terminal domain, which has been shown to be present in the extreme carboxy-terminal region of the PAX2, 5 and 8 class of PAX proteins (Dor¯er and Busslinger, 1996) (MJM, unpublished) . Stuart et al. (1995) found that the p53 gene promoter was repressed by PAX2, PAX5 or PAX8 in cotransfection assays in NIH3T3 cells and rat embryo ®broblasts (REFs) (Stuart et al., 1995) . In this study we also analysed transcriptional regulation of the p53 and N-myc gene promoters by PAX2 in CHO-K1 cells, and although we did not observe signi®cant repression of the p53 promoter by PAX2b, we did observe fourfold activation of p53 promoter activity by the PAX2c isoform (40-fold when compared to the CMV expression vector), and twofold activation of the N-myc promoter by PAX2b and PAX2c in CHO-K1 cells. It is possible that repression of p53, as observed by Stuart et al. (1995) was cell line speci®c. Others have also observed cell line speci®c regulation of target gene promoters in co-transfection assays (Jackson et al., 1993) , perhaps re¯ecting a requirement for speci®c cooperating transcription factors in certain cell lines, or that the transcription factor requires modi®cation in a cell speci®c fashion for activity. Alternatively, because our p53 promoter construct was 71 bp larger than the construct used by Stuart et al. (1995) it may have included a second PAX2 binding site not present in their construct. Interestingly, a site with 10/17 bp identity to the consensus PAX2/5/8 binding site was identi®ed in the ®rst 70 bp of the p53 promoter used here, which was present in addition to the site with a 14/17 bp match to the PAX2/5/8 consensus binding site that had already been identi®ed by Stuart et al. (1995) . This ®nding would be consistent with the hypothesis that two PAX2 binding sites are needed for full transcriptional activation of the p53 promoter by PAX2.
While our data suggest that PAX2 may transcriptionally activate WT1, it has previously been shown that WT1 transcriptionally represses the PAX2 promoter (Ryan et al., 1995) . Therefore the possibility exists that there is cross-transcriptional control between these two genes, such that PAX2 initially modulates the transcriptional activity of WT1 and at a later stage when a threshold level of WT1 protein is reached, the WT1 protein level in cells may then repress PAX2 transcription. Patients with mutations in PAX2 have renal and eye anomalies (renal-coloboma syndrome) including renal hypogenesis and renal failure (Sanyanusin et al., 1995a,b) . It is possible that the PAX2 mutations in these patients lead to lack of WT1 transcription, which may in part be responsible for the poor dierentiation of fetal kidney cells in these patients, or loss of fetal kidney cells by apoptosis. A related eect may be seen in Wilms tumours which contain cells resembling undierentiated fetal kidney. A proportion of Wilms tumours harbour mutations of WT1, but in contrast to patients with mutations in PAX2, the PAX2 gene is persistently expressed in Wilms tumours (Eccles et al., 1995) . This persistent expression of PAX2 may suppress the apoptotic mechanism, and be part of the transformation process. Consistent with this notion, Bernasconi et al. (1996) have recently shown that antisense PAX3 or PAX7 oligonucleotides induced apoptosis in rhabdomyosarcoma cells.
In this study we have found evidence for transactivation of the WT1 promoter by two isoforms of PAX2. Regulation of WT1 by PAX2 may be required for the dierentiation, tissue architectural organisation, and/or cell survival of kidney epithelial cells. In this regard PAX2 as well as WT1 may be key regulators of cell dierentiation and morphogenesis in the mammalian kidney.
Materials and methods

Plasmid constructs
The reporter plasmids (illustrated in Figures 1a and 4a) contained the human WT1, p53 and N-myc gene promoters fused to the luciferase reporter gene of pGL2 basic (Promega). Fragments of the WT1 promoter were derived from clone WTA5 . The full length WT1 promoter reporter clone, pGLWTpS-P, was constructed by excision of a 1.3 kb SacI-PstI fragment from the plasmid pBSWTpXhoI, a subclone of WTA5 in pBluescript II (Stratagene), containing a 2.8 kb XhoI fragment of exon 1 and upstream sequences of WT1. This 1.3 kb fragment was cloned into the luciferase reporter vector pGL2 basic (Promega). pGLWTpX-P was constructed by excision of a 695 bp XbaI to PstI fragment from WTA5, which was cloned into pBluescript II, then excised with SacI and XhoI and subcloned into pGL2 basic. pGLWTpH-P was constructed by excising a HindIII fragment from pGLWTpS-P, which was subcloned directly in pGL2 basic. pGLWTpE-P was constructed by removal of a 271 bp EagI to PstI fragment from pBSWTpXhoI, which was cloned into pBluescriptIISK(7) (Stratagene). The insert was excised with SacI and XhoI and subcloned into pGL2 basic. pGLWTpS-B was constructed by excising a SacI to BssHII fragment from WTA5, which was subcloned into SacI/MluI digested pGL2 basic. pGLWTpS-H was constructed by removal of a HindIII fragment from pGLWTpS-B, and re-ligation. pGLWTpS-X was constructed by excision of a 603 bp SacI to XbaI fragment from pGLWTpS-B and cloned into pGL2 basic digested with SacI and NheI. The primer sequences for amplifying the PCR product encompassing oligonucleotides I and II were WTp#1F; 5' (7299) CCA AGA GGG CGG GAA CTT CAG (7276) 3' and WTp#1R; 5' (7172) TGG CCA CTC CCC TAC CCG ACA GT (7193) 3'. The PCR product was subcloned into pGL2 promoter to generate pGLWTp#1. The p53 promoter region in construct pGLp53p was ampli®ed from genomic DNA by PCR as described previously (Stuart et al., 1995) using Pwo polymerase (Boehringer) and a magnesium sulphate concentration of 1 mM, for 30 cycles with an annealing temperature of 588C, and then subcloned into pBluescript-IISK(7) (Stratagene). The forward primer was 5' (7532) GGG AGA AAA CGT TAG GGT GTG (7512) 3' and the reverse primer was 5' (73) AAT CCA GGG AAG CGT GTC A (721) 3'. The sequence was con®rmed by dideoxy sequencing (Tuck and Crawford, 1989) , and the fragment was subcloned into pGL2 basic. The N-myc promoter construct (pGLN-mycB) was generated from a plasmid containing a 2.9 kb EcoRI fragment spanning exon 1 and 1.8 kb of upstream sequence of the N-myc gene (Takehana et al., 1991) . A 2.0 kb EcoRI ± BamHI fragment, including 151 bp of the 5' region of exon 1, was excised from this plasmid and subcloned into pGL2 basic. PAX2 expression constructs were made by cloning the 5' untranslated and coding sequence of PAX2, with or without exon 10 (PAX2c and PAX2b) (Eccles et al., 1992; Ward et al., 1994) , into Rc/CMV (Invitrogen) containing a modi®ed cloning cassette, downstream of the human cytomegalovirus immediate early promoter.
Cell culture and transfection assays 293 and COS-7 cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) with high glucose, the CHO-K1 cells were grown in Ham F-12. Cultures were supplemented with 10% heat-inactivated fetal calf serum (FCS) and gentamycin sulphate, and grown at 378C in 5% CO 2 . Transfections were carried out using LipofectAMINE reagent (Gibco BRL) in serum-free medium without antibiotics. Cells (5610 5 ) were seeded into 60 mm dishes, and transfected when 70% con¯uent, 16 to 18 h later. DNA for transfection was prepared using QIAGEN tips (QIAGEN), using the manufacturers recommendations under sterile conditions. A total of 2 mg of DNA, containing 1 mg of reporter plasmid and 1 mg of expression plasmid, or alternatively 2 mg of reporter plasmid, was combined with either 8, 10 or 10 mg of LipofectAMINE for transfection of CHO-K1, COS-7 or 293 cells, respectively. The cells were overlaid with this mixture, in a ®nal volume of 1 ml of serum-free media, for 3, 3 or 6 h, respectively, before the addition of 1 ml of normal growth media containing 20% FCS. The media was changed at 24 h. Cells were harvested and lysates assayed for luciferase production at 48 h, using a luciferase assay kit (Promega), following the manufacturers instructions. Transfections were done in triplicate, and each datapoint represents at least three triplicate experiments. Luminescence was measured with either a Berthold or a BioOrbit luminometer. Luciferase activities (RLU) for each construct were expressed per 1 mg of reporter vector transfected, and were calculated as the quotient of the activity of the construct over the activity of pGL2 basic, which was included in each set of transfections to normalize for small variations in transfection eciency. In a series of preliminary experiments, 293 cells were co-transfected with several WT1 promoter-reporter constructs, for example pGLWTpS-B and CMVb-gal, with or without PAX2b or PAX2c. The b-galactosidase activity was measured to determine if the eciency of plasmid uptake was aected by co-transfection of the cells with reporter plasmids and PAX2 constructs, or was highly variable from experiment to experiment. In our hands, the eciency of plasmid transfection in 293 cells did not vary more than twofold within a transfection experiment, or more than threefold from experiment to experiment over the course of ®ve experiments. These experiments suggest that transfection eciency of the cells was not highly variable within a given cell line. 293 cells transfected with pGL2 basic to normalize transfection eciency consistently had approximately 10 times more luciferase activity than mock transfected cells, while CHO-K1 cells had 100 times more luciferase activity than mock-transfected cells, re¯ecting the relative transfection eciencies of each cell line. Mean luciferase activity (RLU) values were calculated from at least nine separate transfection assays.
Production of recombinant PAX2 protein
The PAX2 cDNA coding sequence, with and without exon 10 (PAX2c and PAX2b respectively) (Ward et al., 1994) , was cloned into the pFLAG MAC vector provided with the FLAG protein puri®cation system (IBI). Bacterial FLAG fusion proteins were puri®ed using an immunoanity column, as recommended by the manufacturer, and the puri®ed protein was eluted in glycine buer, neutralized, dialysed, and then stored in 50% glycerol-buer at 7208C. The PAX2 protein used was a full length FLAG-PAX2 fusion protein. In all DNA binding experiments depicted here the assays shown were done with the FLAG-PAX2c fusion protein, although no dierence in DNA binding was observed between the FLAG-PAX2c and FLAG-PAX2b fusion proteins.
Electromobility shift assays (EMSA)
DNA probes for EMSA were made either by PCR with uniform incorporation of [a 32 P]dCTP (Amersham), or by annealing overlapping oligonucleotides and ®lling in the ends with Klenow polymerase, with incorporation of [a 32 P]dCTP (Amersham). All probes were puri®ed from 6% low bis (49 : 1) polyacrylamide gels, eluted overnight, ®ltered and then ethanol precipitated. Approximately 0.5 ng of probe DNA was used in each reaction. Probes were incubated with 100 to 500 ng of puri®ed bacterial full length PAX2 fusion protein at room temperature in a solution containing 100 mM KCl; 10 mM HEPES buer, pH 7.9; 1 mM EDTA, 1 mM DTT; 4% Ficoll, 1 mg poly d(I-C) for 15 min, followed by electrophoresis in 0.56TBE through a 6% polyacrylamide gel. After electrophoresis, polyacrylamide gels were dried and autoradiographed.
DNaseI footprinting
DNaseI footprinting probes were made by digesting a plasmid containing the required sequence with restriction enzymes leaving 5' and 3' overhangs at either end. The digested DNA was extracted with phenol :chloroform : isoamyl alcohol 35 : 34 : 1 (PCI), and ethanol precipitated. M-MLV reverse transcriptase (Life Technologies), [a 32 P]dCTP and [a 32 P]dATP (Amersham) were used to ®ll in the end containing the 5' overhang. The labeled probe was extracted with PCI, ethanol precipitated, and gel puri®ed by electrophoresis through a 6% low bis polyacrylamide gel, followed by overnight elution. Probe DNA, 10 000 c.p.m., was incubated with 200 ± 500 ng of recombinant PAX2 fusion protein at room temperature in a solution containing 100 mM KCl; 10 mM HEPES, pH 7.9; 1 mM EDTA; 1 mM DTT; 4% Ficoll, 1 mg poly d(I-C) for 15 min. Probe DNA-protein complexes were digested with 0.05 ± 0.075 U of RQ-1 DNase I (Promega) for 2 min in a solution containing the probe DNA-protein mixture, 2.5 mM CaCl 2 and 5 mM MgCl 2 . Reactions were stopped by the addition of an equal volume of stop solution (200 mM NaCl; 30 mM EDTA; 1% SDS), extracted with PCI, ethanol precipitated, electrophoresed in a 12% polyacrylamide, 7 M urea gel, dried and autoradiographed.
